144 related articles for article (PubMed ID: 26724472)
1. Response to Crizotinib Observed in Lung Adenocarcinoma with MET Copy Number Gain but without a High-Level MET/CEP7 Ratio, MET Overexpression, or Exon 14 Splicing Mutations.
Zhang Y; Wang W; Wang Y; Xu Y; Tian Y; Huang M; Lu Y
J Thorac Oncol; 2016 May; 11(5):e59-e62. PubMed ID: 26724472
[TBL] [Abstract][Full Text] [Related]
2. Responses to Crizotinib Can Occur in High-Level MET-Amplified Non-Small Cell Lung Cancer Independent of MET Exon 14 Alterations.
Caparica R; Yen CT; Coudry R; Ou SI; Varella-Garcia M; Camidge DR; de Castro G
J Thorac Oncol; 2017 Jan; 12(1):141-144. PubMed ID: 27664533
[TBL] [Abstract][Full Text] [Related]
3. A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib.
Mahjoubi L; Gazzah A; Besse B; Lacroix L; Soria JC
Invest New Drugs; 2016 Jun; 34(3):397-8. PubMed ID: 26892698
[TBL] [Abstract][Full Text] [Related]
4. Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma.
Shea M; Huberman MS; Costa DB
J Thorac Oncol; 2016 Jul; 11(7):e81-2. PubMed ID: 26845194
[No Abstract] [Full Text] [Related]
5. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.
Ou SI; Young L; Schrock AB; Johnson A; Klempner SJ; Zhu VW; Miller VA; Ali SM
J Thorac Oncol; 2017 Jan; 12(1):137-140. PubMed ID: 27666659
[TBL] [Abstract][Full Text] [Related]
6. [Interest of crizotinib in a lung cancer patient with de novo amplification of MET].
Rabeau A; Rouquette I; Vantelon JM; Taranchon-Clermont E; Mazières J
Rev Mal Respir; 2017 Jan; 34(1):57-60. PubMed ID: 27745897
[TBL] [Abstract][Full Text] [Related]
7. Response and acquired resistance to crizotinib in Chinese patients with lung adenocarcinomas harboring MET Exon 14 splicing alternations.
Dong HJ; Li P; Wu CL; Zhou XY; Lu HJ; Zhou T
Lung Cancer; 2016 Dec; 102():118-121. PubMed ID: 27987579
[TBL] [Abstract][Full Text] [Related]
8. Complete response to crizotinib in a patient with adenocarcinoma of the lung cancer harboring c- MET amplification.
Cil I; Zirtiloglu A; Saydam N; Tural D
J BUON; 2017; 22(1):279-280. PubMed ID: 28365967
[No Abstract] [Full Text] [Related]
9. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.
Paik PK; Drilon A; Fan PD; Yu H; Rekhtman N; Ginsberg MS; Borsu L; Schultz N; Berger MF; Rudin CM; Ladanyi M
Cancer Discov; 2015 Aug; 5(8):842-9. PubMed ID: 25971939
[TBL] [Abstract][Full Text] [Related]
10. Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation.
Jenkins RW; Oxnard GR; Elkin S; Sullivan EK; Carter JL; Barbie DA
Clin Lung Cancer; 2015 Sep; 16(5):e101-4. PubMed ID: 25769807
[No Abstract] [Full Text] [Related]
11. Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis.
Noonan SA; Berry L; Lu X; Gao D; Barón AE; Chesnut P; Sheren J; Aisner DL; Merrick D; Doebele RC; Varella-Garcia M; Camidge DR
J Thorac Oncol; 2016 Aug; 11(8):1293-1304. PubMed ID: 27262212
[TBL] [Abstract][Full Text] [Related]
12. MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.
Awad MM; Oxnard GR; Jackman DM; Savukoski DO; Hall D; Shivdasani P; Heng JC; Dahlberg SE; Jänne PA; Verma S; Christensen J; Hammerman PS; Sholl LM
J Clin Oncol; 2016 Mar; 34(7):721-30. PubMed ID: 26729443
[TBL] [Abstract][Full Text] [Related]
13. MET receptor juxtamembrane exon 14 alternative spliced variant: novel cancer genomic predictive biomarker.
Ma PC
Cancer Discov; 2015 Aug; 5(8):802-5. PubMed ID: 26243862
[TBL] [Abstract][Full Text] [Related]
14. MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium.
Guo R; Berry LD; Aisner DL; Sheren J; Boyle T; Bunn PA; Johnson BE; Kwiatkowski DJ; Drilon A; Sholl LM; Kris MG
J Thorac Oncol; 2019 Sep; 14(9):1666-1671. PubMed ID: 31228623
[TBL] [Abstract][Full Text] [Related]
15. Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor.
Benderra MA; Aspeslagh S; Postel-Vinay S; Bigot L; De Baere T; Loriot Y; Lacroix L; Massard C; Vassal G; André F; Soria JC
J Thorac Oncol; 2016 Feb; 11(2):e21-3. PubMed ID: 26845121
[No Abstract] [Full Text] [Related]
16. Precision medicine approaches to lung adenocarcinoma with concomitant MET and HER2 amplification.
Oh DY; Jung K; Song JY; Kim S; Shin S; Kwon YJ; Oh E; Park WY; Song SY; Choi YL
BMC Cancer; 2017 Aug; 17(1):535. PubMed ID: 28806950
[TBL] [Abstract][Full Text] [Related]
17. Acquired resistance to crizotinib in advanced lung adenocarcinoma with MET exon 14 skipping.
Zhang Y; Yin J; Peng F
Lung Cancer; 2017 Nov; 113():69-71. PubMed ID: 29110851
[No Abstract] [Full Text] [Related]
18. Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib.
Wang SXY; Zhang BM; Wakelee HA; Koontz MZ; Pan M; Diehn M; Kunder CA; Neal JW
Anticancer Drugs; 2019 Jun; 30(5):537-541. PubMed ID: 30762593
[TBL] [Abstract][Full Text] [Related]
19. MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values.
Lee GD; Lee SE; Oh DY; Yu DB; Jeong HM; Kim J; Hong S; Jung HS; Oh E; Song JY; Lee MS; Kim M; Jung K; Kim J; Shin YK; Choi YL; Kim HR
J Thorac Oncol; 2017 Aug; 12(8):1233-1246. PubMed ID: 28502721
[TBL] [Abstract][Full Text] [Related]
20. Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer: Results of a Phase I Study.
Jänne PA; Shaw AT; Camidge DR; Giaccone G; Shreeve SM; Tang Y; Goldberg Z; Martini JF; Xu H; James LP; Solomon BJ
J Thorac Oncol; 2016 May; 11(5):737-747. PubMed ID: 26899759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
